Skip to content
Axcess News – Lifestyle
Author:
ProMIS Neurosciences Inc.
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
July 27, 2026
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
July 14, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences in June
May 28, 2026
←
Previous Page
1
2